Nexentis Technologies/$NXTS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nexentis Technologies
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
- Ticker
- $NXTS
- Sector
- Materials
- Primary listing
- NASDAQ
- Employees
- 8
- Headquarters
- Ness Ziona, Israel
- Website
- www.nexentistech.com
NXTS Metrics
BasicAdvanced
$669K
-
-$167.92
1.98
-
Price and volume
Market cap
$669K
Beta
1.98
52-week high
$2.77
52-week low
$2.20
Financial strength
Current ratio
3.718
Quick ratio
3.176
Long term debt to equity
0.118
Total debt to equity
0.239
Interest coverage (TTM)
-0.89%
Profitability
EBITDA (TTM)
-5.974
Effective tax rate (TTM)
0.38%
Management effectiveness
Return on assets (TTM)
-29.54%
Return on equity (TTM)
-454.82%
Valuation
Price to book
0.35
Price to tangible book (TTM)
-0.29
Price to free cash flow (TTM)
-0.042
Free cash flow yield (TTM)
-2,395.21%
Free cash flow per share (TTM)
-55.089
Growth
Earnings per share change (TTM)
-87.61%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.